SEC Tracker
Get the app

Supernus Pharmaceuticals SUPN

Supernus Pharmaceuticals delists after merger

S-8 POS filing

Form
S-8 POS
Filed
Importance
Routine
  1. 1.5401 shares of Indivior common stock per Supernus share
  2. Merger completed on November 2, 2026
  3. Indivior renamed Supernus, Inc.

Written from the S-8 POS on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Supernus Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Sarepta Therapeutics SRPT public float $1.7B, Jun 30, 2025
  2. Amicus Therapeutics FOLD public float $1.7B, Jun 30, 2025
  3. Ocular Therapeutix OCUL public float $1.6B, Jun 30, 2025
  4. Ligand Pharmaceuticals LGND public float $1.6B, Jun 30, 2025
  5. Apellis Pharmaceuticals APLS public float $1.8B, Jun 30, 2025